Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGAV | P06756 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071978 | 0.84 | SMN1; SMN2 (0.48) | ITGB3ITGAV | |
| SCHEMBL2794893 | 0.76 | CTSS (0.49) | MEN1POLBKMT2A | |
| SCHEMBL3504563 | 0.76 | CTSS (0.49) | MEN1POLBKMT2A | |
| SCHEMBL2794895 | 0.76 | CTSS (0.49) | MEN1POLBKMT2A | |
| SCHEMBL9384225 | 0.74 | FPR2 (0.63) | ITGB3MEN1KMT2A | |
| SCHEMBL5926332 | 0.74 | CYP26A1 (0.53) | — | |
| SCHEMBL4885775 | 0.73 | CNR2 (0.49) | MEN1KMT2A | |
| SCHEMBL4890461 | 0.73 | CNR2 (0.49) | MEN1KMT2A | |
| SCHEMBL4885769 | 0.73 | CNR2 (0.49) | MEN1KMT2A | |
| SCHEMBL4097623 | 0.73 | SMN1; SMN2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | ITGB3 2493/4885ITGAV 2495/4885CYP1A2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.